MCID: FLL037
MIFTS: 71

Follicular Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Follicular Lymphoma

MalaCards integrated aliases for Follicular Lymphoma:

Name: Follicular Lymphoma 38 12 76 53 37 29 6 15
Lymphoma, Follicular 53 44 73
Lymphoma Follicular 55

Classifications:



Summaries for Follicular Lymphoma

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 545Disease definitionFollicular lymphoma is a form of non-Hodgkin lymphoma (see this term) characterized by a proliferation of B cells whose nodular structure of follicular architecture is preserved.EpidemiologyPrevalence of follicular lymphoma is estimated at about 1/3,000.Clinical descriptionThe median age at diagnosis is 60-65 years. The disease is extremely rare in children. Follicular lymphoma is located primarily in the lymph nodes, but can also involve the spleen, bone marrow, peripheral blood and Waldeyer's ring. The skin and central nervous system are affected in rare cases. Symptoms appear at an advanced stage of the disease and can include fever, night sweats and weight loss. At diagnosis, patients usually present with adenopathy and, in 50% of cases, splenomegaly.EtiologyIn 85% of cases, follicular lymphomas are associated with a translocation t(14;18) (q32;q21), which activates the BCL2 gene encoding the BCL2 protein that is essential for some apoptosis processes.Diagnostic methodsDiagnosis is based on histological analysis of the adenopathy, a complete blood count, measurement of lactate dehydrogenase (LDH) and biopsy analysis of a lymph node. Examination using imagery (particularly a chest radiograph) is required. The observation of the translocation t(14;18) by polymerase chain reaction (PCR), in addition to suggested histological results, confirms the diagnosis.Differential diagnosisDifferential diagnoses include chronic lymphocytic B cell leukemia, diffuse large B cell lymphoma, mantle cell lymphoma and MALT lymphoma (see these terms).Management and treatmentIf the lymphoma is localized it should be treated by radiotherapy. In the case of advanced stage lymphoma, chemotherapy with immuno-chemotherapy should be offered (rituximab combined with CHOP). In cases of chemosensitive relapse, treatment can be intensified.PrognosisThe survival rate at five years is 80-90% and medial survival is approximately 10-12 years.Visit the Orphanet disease page for more resources.

MalaCards based summary : Follicular Lymphoma, also known as lymphoma, follicular, is related to follicular lymphoma 1 and lymphoma. An important gene associated with Follicular Lymphoma is BCL10 (BCL10, Immune Signaling Adaptor), and among its related pathways/superpathways are Notch signaling pathway (KEGG) and DNA Damage Response. The drugs Arzerra and Zevalin have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are splenomegaly and fever

Disease Ontology : 12 A B-cell lymphoma that is characterized as an indolent non-Hodgkin's lymphoma and has material basis in follicle center B-cells (centrocytes and centroblasts).

Wikipedia : 76 Follicular lymphoma is a type of blood cancer. It is the most common of the indolent (slow-growing)... more...

Related Diseases for Follicular Lymphoma

Diseases in the Follicular Lymphoma family:

Follicular Lymphoma 1

Diseases related to Follicular Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 203)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 1 34.4 BCL10 BCL2 BCL6 FL1
2 lymphoma 32.0 BCL10 BCL2 BCL6 CCND1 KDSR MYC
3 mantle cell lymphoma 31.5 BCL2 BCL6 CCND1 MME MYC
4 nodal marginal zone b-cell lymphoma 31.4 BCL2 BCL6
5 burkitt lymphoma 31.2 AICDA BCL2 BCL6 MIR155 MME MYC
6 primary central nervous system lymphoma 31.1 BCL2 BCL6
7 b-cell lymphomas 31.0 AICDA BCL10 BCL2 BCL6 CCND1 MME
8 diffuse large b-cell lymphoma of the central nervous system 30.8 BCL2 MYC
9 intravascular large b-cell lymphoma 30.7 BCL2 BCL6 MME
10 primary mediastinal large b-cell lymphoma 30.7 BCL2 BCL6 MYC
11 t-cell/histiocyte rich large b cell lymphoma 30.7 BCL6 MME
12 marginal zone b-cell lymphoma 30.5 BCL10 BCL2 BCL6 CCND1 MME
13 lymphoma, mucosa-associated lymphoid type 30.4 BCL10 BCL2 BCL6 CCND1 MME
14 lymphoma, hodgkin, classic 30.4 BCL6 MIR155 MME
15 diffuse large b-cell lymphoma 30.3 BCL6 MIR106A MIR139 MIR149 MIR155 MIR210
16 leukemia, chronic lymphocytic 30.1 AICDA BCL10 BCL2 BCL6 CCND1 MIR181A1
17 lymphoma, non-hodgkin, familial 30.1 AICDA BCL10 BCL2 BCL6 CCND1 MME
18 leukemia, acute lymphoblastic 30.0 MIR155 MIR210 MME
19 cholangiocarcinoma 29.6 CCND1 MIR301A MIR320A MME
20 leukemia, acute myeloid 29.2 MIR155 MIR210 MIR320A MME MYC
21 primary cutaneous follicle center lymphoma 11.5
22 histiocytic and dendritic cell cancer 11.1
23 primary effusion lymphoma 10.8
24 lymphoblastic lymphoma 10.7
25 plasmablastic lymphoma 10.7
26 lymphocytic leukemia 10.4
27 lymphomatoid granulomatosis 10.4
28 leukemia 10.3
29 heart lymphoma 10.3 BCL6 MME
30 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.3 BCL2 BCL6 MYC
31 leukemia, chronic lymphocytic 2 10.3
32 leukemia, b-cell, chronic 10.3
33 lymphoma, small cleaved-cell, diffuse 10.3 BCL2 CCND1
34 gastric lymphoma 10.3 BCL10 BCL2 BCL6
35 chronic venous leg ulcers 10.3 BCL2 MYC
36 sarcoma 10.3
37 lymphatic system cancer 10.3 BCL6 MME MYC
38 mature b-cell neoplasm 10.3 BCL6 MME MYC
39 hematopoietic stem cell transplantation 10.2
40 testicular lymphoma 10.2 BCL6 MME
41 leukemia, acute lymphoblastic 3 10.2
42 splenic marginal zone lymphoma 10.2
43 primary cutaneous diffuse large b-cell lymphoma, leg type 10.2
44 primary cutaneous marginal zone b-cell lymphoma 10.2
45 alk-positive large b-cell lymphoma 10.2
46 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 10.2
47 splenic diffuse red pulp small b-cell lymphoma 10.2
48 diffuse large b-cell lymphoma with chronic inflammation 10.2
49 lymphoplasmacytic lymphoma without igm production 10.2
50 extramedullary plasmacytoma 10.2 BCL2 CCND1

Graphical network of the top 20 diseases related to Follicular Lymphoma:



Diseases related to Follicular Lymphoma

Symptoms & Phenotypes for Follicular Lymphoma

Human phenotypes related to Follicular Lymphoma:

32 (show all 12)
# Description HPO Frequency HPO Source Accession
1 splenomegaly 32 frequent (33%) HP:0001744
2 fever 32 hallmark (90%) HP:0001945
3 fatigue 32 frequent (33%) HP:0012378
4 weight loss 32 hallmark (90%) HP:0001824
5 lymphedema 32 occasional (7.5%) HP:0001004
6 meningitis 32 occasional (7.5%) HP:0001287
7 lymphoma 32 hallmark (90%) HP:0002665
8 mediastinal lymphadenopathy 32 hallmark (90%) HP:0100721
9 abnormality of the peritoneum 32 occasional (7.5%) HP:0002585
10 pleural effusion 32 occasional (7.5%) HP:0002202
11 skin nodule 32 occasional (7.5%) HP:0200036
12 night sweats 32 hallmark (90%) HP:0030166

Drugs & Therapeutics for Follicular Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
2
Zevalin 18 49 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002

Drugs for Follicular Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 527)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
2
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 24356-66-9 32326 21704
3
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
5
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
6
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
7 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
14 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
17 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
19
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
20
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
21
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
22
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
23
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
24
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
25
Chlorambucil Approved Phase 3 305-03-3 2708
26
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
28
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
29
Iodine Approved, Investigational Phase 3,Phase 1,Phase 2 7553-56-2 807
30
Pixantrone Approved, Investigational Phase 3,Phase 2,Phase 1 144510-96-3
31
Idarubicin Approved Phase 3 58957-92-9 42890
32
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
33 Orange Approved Phase 3
34
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
35
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
36
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
37
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
38
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
39
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
40
Ofloxacin Approved Phase 3 82419-36-1 4583
41
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
42
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
43
Etoposide Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
44
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
45
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
46
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
47
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
48
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
49
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
50
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 1167)
# Name Status NCT ID Phase Drugs
1 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
2 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
3 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
4 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
5 A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients Unknown status NCT01303887 Phase 3 Rituximab;Cyclophosphamide;Vincristine;Prednisolone;Fludarabine
6 Multicentric Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Patients With Stage II−IV Follicular Lymphoma Unknown status NCT00774826 Phase 3 R-CVP;R-CHOP;R-FM
7 Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma Unknown status NCT00435955 Phase 3 Rituximab
8 Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma Unknown status NCT00028691 Phase 3 chlorambucil
9 Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma Unknown status NCT00091676 Phase 3
10 Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
11 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00006250 Phase 3 chlorambucil;dexamethasone;fludarabine phosphate;mitoxantrone hydrochloride
12 Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
13 A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma Unknown status NCT00078598 Phase 3 Rituximab or Iodine I 131 Tositumomab Therapy
14 Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00022685 Phase 3
15 Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma Unknown status NCT00463463 Phase 3 90Yttrium Ibritumomab Tiuxetan (Zevalin)
16 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
17 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
18 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
19 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
20 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
21 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
22 Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
23 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
24 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
25 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
26 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
27 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
28 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
29 High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
30 High-Dose Therapy Treatment in Patients With Follicular Lymphoma Completed NCT00696735 Phase 3
31 A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) Completed NCT02213263 Phase 3
32 A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma Completed NCT02569996 Phase 3 Rituximab
33 GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) Completed NCT03814785 Phase 3
34 Randomized Study for Patients With Follicular Lymphoma Needing Treatment Completed NCT00140569 Phase 3 fludarabine
35 GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma Completed NCT01419665 Phase 3
36 Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden Completed NCT00136552 Phase 3 rituximab
37 Primary Rituximab and Maintenance Completed NCT00140582 Phase 3 Rituximab
38 Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma Completed NCT00227695 Phase 3
39 Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy Completed NCT00185393 Phase 3
40 A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma Completed NCT01200758 Phase 3 Rituximab SC;Rituximab IV;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone/Prednisolone
41 A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) Completed NCT00719472 Phase 3 Rituximab;CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone);CVP (cyclophosphamide, vincristine, prednisone);Analgesic/antipyretic and antihistamine drugs
42 MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma Completed NCT01987505 Phase 3 Rituximab
43 A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL) Completed NCT01144364 Phase 3 rituximab [Mabthera/Rituxan]
44 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
45 Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma Completed NCT00310167 Phase 3
46 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Completed NCT00005589 Phase 3 carmustine;cyclophosphamide;cytarabine;etoposide;melphalan
47 Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma Completed NCT00268983 Phase 3
48 Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102) Completed NCT00168740 Phase 3 rituximab
49 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma Completed NCT00004179 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
50 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2

Search NIH Clinical Center for Follicular Lymphoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Follicular Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, follicular

Genetic Tests for Follicular Lymphoma

Genetic tests related to Follicular Lymphoma:

# Genetic test Affiliating Genes
1 Follicular Lymphoma 29

Anatomical Context for Follicular Lymphoma

MalaCards organs/tissues related to Follicular Lymphoma:

41
B Cells, Bone, Bone Marrow, T Cells, Lymph Node, Skin, Spleen

Publications for Follicular Lymphoma

Articles related to Follicular Lymphoma:

(show top 50) (show all 1621)
# Title Authors Year
1
Outcome of patients with early-stage follicular lymphoma staged with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone. ( 30083824 )
2019
2
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. ( 29934061 )
2018
3
Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway. ( 29923173 )
2018
4
Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) and all-trans retinoic acid (ATRA). ( 29963527 )
2018
5
Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. ( 29898619 )
2018
6
Clinical management and outcomes of completely resected stage I follicular lymphoma. ( 29415976 )
2018
7
Predictive gene-expression score for follicular lymphoma. ( 29893256 )
2018
8
Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study). ( 29901705 )
2018
9
The combination of TRAIL and MG-132 induces apoptosis in both TRAIL-sensitive and TRAIL-resistant human follicular lymphoma cells. ( 29407584 )
2018
10
Consolidation and maintenance in follicular lymphoma: radioimmunotherapy revisited? ( 29396095 )
2018
11
Patient selection and timing of allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma. ( 29927482 )
2018
12
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study. ( 29396094 )
2018
13
From genetics to the clinic: a translational perspective on follicular lymphoma. ( 29422597 )
2018
14
Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. ( 29424927 )
2018
15
Immunohistochemical Reappraisal Regarding the Frequency of Primary Salivary Gland Follicular Lymphoma. ( 29972093 )
2018
16
Gastric follicular lymphoma: A report of 3 cases and a review of the literature. ( 29963140 )
2018
17
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. ( 29317554 )
2018
18
Current and future therapeutic approaches for the treatment of follicular lymphoma. ( 29972084 )
2018
19
Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study. ( 29976619 )
2018
20
Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee. ( 29377067 )
2018
21
The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. ( 29318369 )
2018
22
Lichenoid paraneoplastic pemphigus associated with follicular lymphoma without detectable autoantibodies. ( 29761536 )
2018
23
Extracutaneous variant of juvenile xanthogranuloma in an adult patient associated to follicular lymphoma. ( 29685314 )
2018
24
Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry. ( 29362504 )
2018
25
Follicular lymphoma: 2018 update on diagnosis and management. ( 29314206 )
2018
26
Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-I+ induces prolonged clinical and molecular remissions in patients with follicular lymphoma. ( 29380359 )
2018
27
A renaissance for autologous transplantation in follicular lymphoma? ( 29966478 )
2018
28
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus<sup>131</sup>I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. ( 29356608 )
2018
29
Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. ( 29966465 )
2018
30
Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. ( 29975623 )
2018
31
Predictive gene-expression score for follicular lymphoma. ( 29893255 )
2018
32
Cancer Immunotherapy and the Immune Response in Follicular Lymphoma. ( 29974035 )
2018
33
Predictive gene-expression score for follicular lymphoma - Authors' reply. ( 29893257 )
2018
34
Hepatitis C virus infection is an independent prognostic factor in follicular lymphoma. ( 29416725 )
2018
35
A watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma. ( 29377265 )
2018
36
Positive Results for Tazemetostat in Follicular Lymphoma. ( 29980507 )
2018
37
Gastrointestinal follicular lymphoma: Current knowledge and future challenges. ( 29292593 )
2018
38
A leukemic double-hit follicular lymphoma associated with a complex variant translocation, t(8;14;18)(q24;q32;q21), involving BCL2, MYC, and IGH. ( 29310838 )
2018
39
Gamma heavy-chain disease accompanied with follicular lymphoma: a case report. ( 29472805 )
2018
40
Reversible rituximab-induced rectal Kaposi's sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma. ( 29992013 )
2018
41
Congestive heart failure in older adults diagnosed with follicular lymphoma: A population-based study. ( 30303522 )
2018
42
Simultaneous Presence of Follicular Lymphoma, Diffuse Large B-cell Lymphoma, and Hodgkin-like Lymphoma ( 30398157 )
2018
43
Transformation of jejunoileal follicular lymphoma into diffuse large B-cell lymphoma detected using double-balloon enteroscopy. ( 30021733 )
2018
44
Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study. ( 30058572 )
2018
45
Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. ( 30112190 )
2018
46
Follicular Lymphoma mimicking Metastatic Nodes on the F-18 FDG PET/CT and MRI for Staging of Endometrial Cancer. ( 29662565 )
2018
47
Transformed Follicular Lymphoma (TFL) Predicts Outcome in Advanced Endometrial Cancer. ( 29784731 )
2018
48
Further Examining the TROG 99.03 Trial in Early-Stage Follicular Lymphoma: Cure Rate and the Role of Positron Emission Tomography. ( 30475666 )
2018
49
BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma. ( 30480474 )
2018
50
Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. ( 30481079 )
2018

Variations for Follicular Lymphoma

ClinVar genetic disease variations for Follicular Lymphoma:

6 (show all 12)
# Gene Variation Type Significance SNP ID Assembly Location
1 BCL10 NM_003921.4(BCL10): c.427_428dupTT (p.Glu145Leufs) duplication Pathogenic rs587776632 GRCh37 Chromosome 1, 85733584: 85733585
2 BCL10 NM_003921.4(BCL10): c.427_428dupTT (p.Glu145Leufs) duplication Pathogenic rs587776632 GRCh38 Chromosome 1, 85267901: 85267902
3 BCL10 NM_003921.4(BCL10): c.231dupA (p.Gly78Argfs) duplication Pathogenic rs587776633 GRCh37 Chromosome 1, 85736416: 85736416
4 BCL10 NM_003921.4(BCL10): c.231dupA (p.Gly78Argfs) duplication Pathogenic rs587776633 GRCh38 Chromosome 1, 85270733: 85270733
5 BCL10 NM_003921.4(BCL10): c.525_541del17 (p.Val176Asnfs) deletion Pathogenic rs587776634 GRCh37 Chromosome 1, 85733471: 85733487
6 BCL10 NM_003921.4(BCL10): c.525_541del17 (p.Val176Asnfs) deletion Pathogenic rs587776634 GRCh38 Chromosome 1, 85267788: 85267804
7 BCL10 NM_003921.4(BCL10): c.410delA (p.Asn137Ilefs) deletion Pathogenic rs587776635 GRCh37 Chromosome 1, 85733602: 85733602
8 BCL10 NM_003921.4(BCL10): c.410delA (p.Asn137Ilefs) deletion Pathogenic rs587776635 GRCh38 Chromosome 1, 85267919: 85267919
9 BCL10 NM_003921.4(BCL10): c.398dupT (p.Ser134Leufs) duplication Pathogenic rs587776636 GRCh37 Chromosome 1, 85733614: 85733614
10 BCL10 NM_003921.4(BCL10): c.398dupT (p.Ser134Leufs) duplication Pathogenic rs587776636 GRCh38 Chromosome 1, 85267931: 85267931
11 BCL10 NM_003921.4(BCL10): c.635_637delAAG (p.Glu212del) deletion Pathogenic rs587776637 GRCh37 Chromosome 1, 85733375: 85733377
12 BCL10 NM_003921.4(BCL10): c.635_637delAAG (p.Glu212del) deletion Pathogenic rs587776637 GRCh38 Chromosome 1, 85267692: 85267694

Cosmic variations for Follicular Lymphoma:

9 (show top 50) (show all 1085)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6932312 XIAP haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1209C>A p.N403K 23:123900602-123900602 7
2 COSM43956 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.700T>A p.Y234N 17:7674263-7674263 7
3 COSM10662 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.743G>A p.R248Q 17:7674220-7674220 7
4 COSM10749 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.830G>T p.C277F 17:7673790-7673790 7
5 COSM6932 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.733G>A p.G245S 17:7674230-7674230 7
6 COSM44198 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.653T>G p.V218G 17:7674878-7674878 7
7 COSM44026 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.559G>A p.G187S 17:7675053-7675053 7
8 COSM11059 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.713G>A p.C238Y 17:7674250-7674250 7
9 COSM43565 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.857A>G p.E286G 17:7673763-7673763 7
10 COSM44579 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.783T>G p.S261R 17:7673837-7673837 7
11 COSM44578 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.721T>C p.S241P 17:7674242-7674242 7
12 COSM44459 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.777C>A p.D259E 17:7674186-7674186 7
13 COSM6987596 TNFRSF14 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.332G>A p.C111Y 1:2559850-2559850 7
14 COSM6987662 TNFAIP3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,follicular lymphoma c.1344G>A p.W448* 6:137878789-137878789 7
15 COSM6987340 TMEM127 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.660C>G p.Y220* 2:96253865-96253865 7
16 COSM100055 TET2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.4256C>G p.P1419R 4:105272637-105272637 7
17 COSM6932384 STK11 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1051G>C p.E351Q 19:1223115-1223115 7
18 COSM6987665 STAG2 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,follicular lymphoma c.2550T>G p.D850E 23:124076348-124076348 7
19 COSM211661 SRSF2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.284C>G p.P95R 17:76736877-76736877 7
20 COSM36143 SOCS1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.127C>T p.P43S 16:11255352-11255352 7
21 COSM36144 SOCS1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.347G>A p.S116N 16:11255132-11255132 7
22 COSM6932386 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.3197C>T p.T1066I 19:11026328-11026328 7
23 COSM6955363 ROS1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1818G>T p.Q606H 6:117387976-117387976 7
24 COSM6935204 RHOA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.172T>C p.W58R 3:49368533-49368533 7
25 COSM5064959 RHOA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.109A>G p.T37A 3:49375481-49375481 7
26 COSM5930230 RHOA haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.190G>A p.E64K 3:49368515-49368515 7
27 COSM6932382 RAD54L haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1274A>G p.K425R 1:46272701-46272701 7
28 COSM6947130 PTPRD haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.5380-2A>T p.? 9:8331738-8331738 7
29 COSM6987599 PTEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.497T>A p.V166E 10:87952122-87952122 7
30 COSM6987342 PRDM1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.66T>A p.C22* 6:106088332-106088332 7
31 COSM6987506 PIM1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.97C>A p.P33T 6:37170787-37170787 7
32 COSM563 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.34G>A p.G12S 1:114716127-114716127 7
33 COSM6987169 MEF2B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.571C>T p.H191Y 19:19146846-19146846 7
34 COSM220509 MEF2B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.205T>C p.Y69H 19:19149279-19149279 7
35 COSM4170995 MEF2B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.10A>G p.K4E 19:19150726-19150726 7
36 COSM6987172 MED12 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.4312T>G p.S1438A 23:71132435-71132435 7
37 COSM4767356 MED12 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.122T>G p.V41G 23:71119395-71119395 7
38 COSM6933961 MAP3K13 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.1317G>T p.K439N 3:185463588-185463588 7
39 COSM6987199 MAP2K1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.388T>A p.Y130N 15:66436842-66436842 7
40 COSM6987344 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.11848C>T p.Q3950* 12:49032047-49032047 7
41 COSM6987127 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.9601C>T p.Q3201* 12:49034611-49034611 7
42 COSM1717602 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.7390C>T p.R2464* 12:49039464-49039464 7
43 COSM6932304 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.10768C>T p.Q3590* 12:49033127-49033127 7
44 COSM6932306 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.9913C>T p.Q3305* 12:49034084-49034084 7
45 COSM6987682 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.5899C>T p.Q1967* 12:49041061-49041061 7
46 COSM6986948 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.839+2T>A p.? 12:49053474-49053474 7
47 COSM2007058 KMT2D haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.6730C>T p.Q2244* 12:49040230-49040230 7
48 COSM6986588 INPP4B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.245A>C p.E82A 4:142405216-142405216 7
49 COSM6986585 INPP4B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.2135G>A p.R712Q 4:142122128-142122128 7
50 COSM6987179 IFNGR1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,follicular lymphoma c.302G>C p.R101T 6:137206207-137206207 7

Copy number variations for Follicular Lymphoma from CNVD:

7 (show top 50) (show all 76)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13361 1 1 12700000 Copy number Follicular lymphoma
2 13749 1 1 27800000 Loss Follicular lymphoma
3 15761 1 119415209 120497765 Amplification NOTCH2 Follicular lymphoma
4 17512 1 143222462 153482569 Copy number ADAM15 Follicular lymphoma
5 17513 1 143222462 153482569 Copy number BCL9 Follicular lymphoma
6 17514 1 143222462 153482569 Copy number IL6R Follicular lymphoma
7 17515 1 143222462 153482569 Copy number MCL1 Follicular lymphoma
8 17516 1 143222462 153482569 Copy number PIAS3 Follicular lymphoma
9 17517 1 143222462 153482569 Copy number TNFAIP8L2 Follicular lymphoma
10 20608 1 153300000 154800000 Gain Follicular lymphoma
11 21393 1 158419998 161795584 Copy number DDR2 Follicular lymphoma
12 21394 1 158419998 161795584 Copy number PEX19 Follicular lymphoma
13 21395 1 158419998 161795584 Copy number UHMK1 Follicular lymphoma
14 25231 1 185800000 214500000 Gain Follicular lymphoma
15 54389 11 43400000 52900000 Gain Follicular lymphoma
16 61270 11 97200000 110400000 Gain Follicular lymphoma
17 65472 12 18053500 31175376 Amplification KRAS Follicular lymphoma
18 65473 12 18053500 31175376 Amplification PIK3C2G Follicular lymphoma
19 65474 12 18053500 31175376 Amplification RASSF8 Follicular lymphoma
20 65475 12 18053500 31175376 Amplification RERGL Follicular lymphoma
21 65476 12 18053500 31175376 Amplification SSPN Follicular lymphoma
22 67780 12 44600000 56300000 Gain Follicular lymphoma
23 69831 12 56316396 72147648 Copy number CDK4 Follicular lymphoma
24 69832 12 56316396 72147648 Copy number DYRK2 Follicular lymphoma
25 69833 12 56316396 72147648 Copy number FRS2 Follicular lymphoma
26 69834 12 56316396 72147648 Copy number IL22 Follicular lymphoma
27 69835 12 56316396 72147648 Copy number MDM2 Follicular lymphoma
28 69836 12 56316396 72147648 Copy number OS9 Follicular lymphoma
29 69837 12 56316396 72147648 Copy number RAB21 Follicular lymphoma
30 69838 12 56316396 72147648 Copy number RAP1B Follicular lymphoma
31 69839 12 56316396 72147648 Copy number RASSF3 Follicular lymphoma
32 69840 12 56316396 72147648 Copy number TBK1 Follicular lymphoma
33 69841 12 56316396 72147648 Copy number TSPAN31 Follicular lymphoma
34 69842 12 56316396 72147648 Copy number WIF1 Follicular lymphoma
35 69843 12 56316396 72147648 Copy number YEATS4 Follicular lymphoma
36 71140 12 67700000 71500000 Gain Follicular lymphoma
37 74580 13 109100000 114142980 Loss Follicular lymphoma
38 79541 13 73300000 79000000 Gain Follicular lymphoma
39 88260 14 88900000 106368585 Loss Follicular lymphoma
40 88262 14 88900000 106368585 Translocation Follicular lymphoma
41 92360 15 40100000 102531392 Loss Follicular lymphoma
42 97239 16 1 16700000 Gain Follicular lymphoma
43 106783 17 1 22200000 Deletion Follicular lymphoma
44 106829 17 1 24000000 Loss Follicular lymphoma
45 107553 17 15900000 22200000 Gain Follicular lymphoma
46 111280 17 35400000 47600000 Gain Follicular lymphoma
47 118113 17 7571720 7590868 Mutation P53 Follicular lymphoma
48 119191 18 1 59800000 Gain Follicular lymphoma
49 120855 18 33040900 33600413 Amplification BRUNOL4 Follicular lymphoma
50 121287 18 41800000 59800000 Translocation Follicular lymphoma

Expression for Follicular Lymphoma

LifeMap Discovery
Genes differentially expressed in tissues of Follicular Lymphoma patients vs. healthy controls: 35 (show top 50) (show all 56)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 FCRLA Fc receptor-like A Intestine + 6.40 0.000
2 SERPINA9 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9 Intestine + 5.98 0.000
3 VPREB3 pre-B lymphocyte 3 Intestine + 5.82 0.000
4 STAG3 stromal antigen 3 Intestine + 5.61 0.000
5 SNX22 sorting nexin 22 Intestine + 5.59 0.000
6 NLRP4 NLR family, pyrin domain containing 4 Intestine + 4.89 0.004
7 LTF lactotransferrin Intestine + 4.72 0.001
8 FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) Intestine + 4.70 0.000
9 AIM2 absent in melanoma 2 Intestine + 4.66 0.000
10 P2RX5 purinergic receptor P2X, ligand gated ion channel, 5 Intestine + 4.54 0.000
11 BFSP2 beaded filament structural protein 2, phakinin Intestine + 4.33 0.000
12 DOK7 docking protein 7 Intestine + 4.29 0.000
13 KLHL14 kelch-like family member 14 Intestine + 4.26 0.000
14 GPR18 G protein-coupled receptor 18 Intestine + 4.26 0.000
15 PAX5 paired box 5 Intestine + 4.21 0.000
16 CNR1 cannabinoid receptor 1 (brain) Intestine + 4.15 0.001
17 PMCH pro-melanin-concentrating hormone Intestine + 4.09 0.000
18 AFF3 AF4/FMR2 family, member 3 Intestine + 4.02 0.000
19 MMP12 matrix metallopeptidase 12 Intestine + 3.94 0.001
20 LOC613266 uncharacterized LOC613266 Intestine + 3.92 0.000
21 C17orf99 chromosome 17 open reading frame 99 Intestine + 3.88 0.003
22 PCDHGB3 protocadherin gamma subfamily B, 3 Intestine + 3.82 0.002
23 TMEM156 transmembrane protein 156 Intestine + 3.81 0.000
24 FCRL2 Fc receptor-like 2 Intestine + 3.76 0.001
25 SCIMP SLP adaptor and CSK interacting membrane protein Intestine + 3.75 0.000
26 CCL17 chemokine (C-C motif) ligand 17 Intestine + 3.73 0.004
27 VNN2 vanin 2 Intestine + 3.71 0.000
28 OR13A1 olfactory receptor, family 13, subfamily A, member 1 Intestine + 3.59 0.001
29 PCDHGB2 protocadherin gamma subfamily B, 2 Intestine + 3.53 0.001
30 CYP4F11 cytochrome P450, family 4, subfamily F, polypeptide 11 Intestine - 3.53 0.015
31 APOBEC2 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 2 Intestine - 3.51 0.003
32 KIAA1549L KIAA1549-like Intestine + 3.45 0.003
33 TCL6 T-cell leukemia/lymphoma 6 (non-protein coding) Intestine + 3.41 0.005
34 AFF2 AF4/FMR2 family, member 2 Intestine + 3.35 0.006
35 CD37 CD37 molecule Intestine + 3.24 0.000
36 IL22RA2 interleukin 22 receptor, alpha 2 Intestine + 3.22 0.012
37 ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 Intestine + 3.22 0.001
38 ARHGAP24 Rho GTPase activating protein 24 Intestine + 3.21 0.001
39 PLEKHG7 pleckstrin homology domain containing, family G (with RhoGef domain) member 7 Intestine + 3.20 0.000
40 CAPN14 calpain 14 Intestine + 3.20 0.002
41 SPANXN3 SPANX family, member N3 Intestine - 3.18 0.002
42 TMEM155 transmembrane protein 155 Intestine + 3.16 0.002
43 RPS16P5 ribosomal protein S16 pseudogene 5 Intestine + 3.15 0.000
44 SLC7A10 solute carrier family 7 (neutral amino acid transporter light chain, asc system), member 10 Intestine + 3.15 0.002
45 SLC5A12 solute carrier family 5 (sodium/monocarboxylate cotransporter), member 12 Intestine - 3.13 0.000
46 PCDH11Y protocadherin 11 Y-linked Intestine + 3.13 0.001
47 BEND4 BEN domain containing 4 Intestine + 3.13 0.001
48 PCDHGA5 protocadherin gamma subfamily A, 5 Intestine + 3.12 0.006
49 MYBL1 v-myb avian myeloblastosis viral oncogene homolog-like 1 Intestine + 3.11 0.008
50 PDCD1 programmed cell death 1 Intestine + 3.09 0.001
Search GEO for disease gene expression data for Follicular Lymphoma.

Pathways for Follicular Lymphoma

GO Terms for Follicular Lymphoma

Cellular components related to Follicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 KDSR MIR106A MIR139 MIR155 MIR181A1 MIR210
2 micro-ribonucleoprotein complex GO:0035068 9.28 MIR106A MIR139 MIR149 MIR155 MIR181A1 MIR210

Biological processes related to Follicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.62 BCL2 BCL6 CCND1 MYC
2 B cell differentiation GO:0030183 9.43 AICDA BCL2 BCL6
3 positive regulation of smooth muscle cell migration GO:0014911 9.4 BCL2 MYC
4 response to iron ion GO:0010039 9.37 BCL2 CCND1
5 gene silencing by miRNA GO:0035195 9.32 MIR106A MIR139 MIR149 MIR155 MIR181A1 MIR210
6 miRNA mediated inhibition of translation GO:0035278 9.26 MIR106A MIR155 MIR181A1 MIR210
7 re-entry into mitotic cell cycle GO:0000320 9.16 CCND1 MYC

Molecular functions related to Follicular Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.26 BCL10 BCL2 CCND1 MYC
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR106A MIR149 MIR155 MIR181A1 MIR210 MIR301A

Sources for Follicular Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....